HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Galidesivir

HCID 10445549
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
249503-25-1
Standard SMILES
Nc1ncnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12
InChIKey
AMFDITJFBUXZQN-KUBHLMPHSA-N
Molecular formula
C11H15N5O3
Average molar mass
265.27 g/mol
Monoisotopic mass
265.11748936

Overview

Galidesivir is an adenosine analogue that has been investigated for use against Zaire Ebolavirus. In animal studies, galidesivir was effective in increasing the survival rates from infections caused by various pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. In vitro, it displayed broad-spectrum antiviral activity against various negative- and positive-sense RNA viruses, including coronaviruses, filoviruses, and arenaviruses. Phase 1 clinical trials have begun to determine the safety of this drug in humans. Because of its activity against other coronaviruses, it may be studied as a potential therapy for COVID-19.

Names & identifiers

Preferred name
Galidesivir
IUPAC
(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol
English name
3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, (2S,3S,4R,5R)-
Molecular formula
C11H15N5O3
Molecular weight
265.27

Names & synonyms

Galidesivir249503-25-1IMMUCILLIN AImmucillin-ABCX4430(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diolImmA cpdOLF97F86A73,4-PYRROLIDINEDIOL, 2-(4-AMINO-5H-PYRROLO(3,2-D)PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)-, (2S,3S,4R,5R)-DTXSID0010280392-(4-Amino-5H-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diolgalidesivirum
Show more names
BCX4430 (freebase)GALIDESIVIR (BCX 4430)BCX4430 freebase (Galidesivir)3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, (2S,3S,4R,5R)-
(2S,3S,4R,5R)-2-(4-amino-5H-pyrrolo(3,2-d)pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diolRefChem:142164DTXCID001513602BCX 4430BCX4430 freebaseBCX-44303,4-Pyrrolidinediol,2-(4-Amino-5h-Pyrrolo[3,2-D]pyrimidin-7-Yl)-5-(Hydroxymethyl)-2s,3s,4r,5rUNII-OLF97F86A7

Database identifiers

CAS
249503-25-1
PubChem CID
10445549
ChEMBL
CHEMBL1236524、CHEMBL1255971
UNII
OLF97F86A7
Nikkaji
J1.272.375J、J1.666.735H

Properties

Computed structural propertiesFilling in

XLogP
-2.1
Topological polar surface area
140 Ų
Hydrogen bond donors
6
Hydrogen bond acceptors
7
Rotatable bonds
2
Heavy atoms
19
Formal charge
0
Complexity
333

Experimental & physicochemical properties

DrugsPharmaceuticals -> Listed in ZINC15

Physicochemical properties

Boiling point
661.2 · 661.2±55.0 °C(Predicted)
Density
1.63 · 1.630±0.06 g/cm3(Predicted)
storage temp.
-20 °C · Store at -20°C
form
Solid
pka
13.78 · 13.78±0.40(Predicted)
color
White to off-white
Water Solubility
1.53 mg/mL · Water : 1.53 mg/mL (5.77 mM)
FDA UNII
97 F86A7 · OLF97F86A7

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

Hazard information

Regulatory Information · 1 item

3,4-Pyrrolidinediol, 2-(4-amino-5H-pyrrolo3,2-dpyrimidin-7-yl)-5-(hydroxymethyl)-, (2S,3S,4R,5R)-: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Chemistry & industry

Pharmacology

Pharmacodynamics · 1 item

Galidesivir is an adenosine analogue with a broad-spectrum antiviral activity against RNA viruses, including flaviviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, coronaviruses, filoviruses, orthomyxoviruses, and picornaviruses.

Mechanism of Action · 1 item

Galidesivir works by binding to viral RNA polymerase where the natural nucleotide would bind, leading to the structural change in the viral enzyme due to altered electrostatic interactions. Disruption of viral RNA polymerase activity results in premature termination of the elongating RNA strand.

MeSH Pharmacological Classification · 1 item

Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.

Applications · 1 item

UsesGalidesivir (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM[1][2][3].

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes